Inhibition of cholesterogenesis decreases hepatic secretion of apoB-100 in normolipidemic subjects

American Journal of Physiology

Volumn 273, Issue 3 PART 1, 1997, Pages

  Watts, G R ^a   Naoumova, R P ^b   Kelly, J M ^c   Riches, F M ^a   Croft, K D ^b   Thompson, G R ^c  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b HAMMERSMITH HOSPITAL   (United Kingdom)

^c ROYAL PERTH HOSPITAL   (Australia)

Author keywords

3 hydroxy 3 methylglutaryl coenzyme areductase; Apolipoprotein b 100; Cholesterol intermediates; Liver; Stable isotope

Indexed keywords

EID: 33745398874     PISSN: 00029513     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Arad, Y., R. Ramakrishnan, and H. N. Ginsbcrg. Lovastatin therapy reduces low density lipoprotein apo B levels in subjects with combined hyperlipidaernia by reducing the production of apoB-containing lipoproteins: implications for the pathophysiology of apoB production. J. LipidRes. 31: 567-582, 1990.
2. 13C]leucine infusion in normal volunteers. Eur. J. Clin. Invest. 23: 602-614, 1993.
3. Benoist, F., and T. Grand-Perret. ApoB-100 secretion by HepG2 cells is regulated by the rate of triglycéride biosynthesis but not by intracellular lipid pools. Arterioscler. Thromb. Vasc. Biol. 16:1229-1235, 1996.
4. Burnett, J. R., L. J. Wilcox, D. E. Telford, S. J. Kleinstiver, P. H. R. Barrett, R. S. Newton, and M. W. Huff. Inhibition of apoB secretion by atorvastatin, in vivo, is correlated with decreased hepatic apoB mRNA abundance. Circulation 94, Suppl. 1:1-632, 1996.
5. Cianflone, K. M., Z. Yasrud, M. A. Rodriguez, D. Vos, and A. D. Sniderman. Regulation of apoB secretion from HepG2 cells: evidence for a critical role for cholesterol ester synthesis in the response to a fatty acid challenge. J. Lipid Res. 31: 2045-2055, 1990.
6. Cobelli, C., G. Toffolo, and D. M. Foster. Tracer-to-tracee ratio for analysis of stable isotope tracer data: link with radioactive kinetic formalism. Am. J. Physiol. 262 (EndocrinoL Metab. 25): E968-E975, 1992.
7. Cook, G. A., B. Khan, and M. Heimberg. Feeding of lovastatin to rats increases the activity of the hepatic mitochondrial outer carnitine palmitoyltransferase. Kochern. Biophys. Res. Commun. 150: 1077-1082, 1988.
8. Cortese, C., Y. Levy, E. D. Janus, P. R. Turner, S. N. Rao, N. E. Millar, and B. Lewis. Modes of action of lipid-lowering diets in man: studies of apolipoprotein B kinetics in relation to fat consumption and dietary fatty acid composition. Eur. J. Clin. Invent. 13: 79-85, 1983.
9. Cummings, M. H., and G. F. Watts. Stable isotopes in lipoprotein research: kinetic studies of very low density lipoprotein apolipoprotein B-100 metabolism in human subjects. Endocrinol. Metab. 3: 78-89, 1996.
10. Dashti, N. The effect of low density lipoproteins, cholesterol, and 25-hydroxycholesterol on apolipoproteinB gene expression in Hep G2 cells. J. Biol. Chem. 267: 7160-7169, 1992.
11. Demant, T., D. Bedford, C. J. Packard, and J. Shepherd. Influence of apolipoprotein E polymorphism on apolipoprotein B-100 metabolism in normolipidaemic subjects. J. Clin. Invest. 88:1490-1501, 1991.
12. Duane, W. C. Serum lathosterol levels in human subjects reflect changes in whole body cholesterol synthesis induced by lovastatin but not dietary cholesterol. J. Lipid Res. 36: 343-348, 1995.
13. Egusa, G., D. W. Brady, S. M. Grundy, and B. V. Howard. Isopropanol precipitation method for the determination of apolipoprotein B specific activity and plasma concentrations during metabolic studies of very low density lipoprotein and low density lipoprotein apolipoprotein B. J. Lipid Res. 24: 1261-1267, 1983.
14. Elmberger, P. G., A. Kaien, E. Lund, E. Reihner, M. Eriksson, L. Berglund, B. Angelin, and G. Daliner. Effects of pravastatin and cholestyramine on products of the mevalonate pathway in familial hypercholesterolaemia. J. Lipid Res. 32: 935-940, 1991.
15. Forster, F., G. Stewart, D. K. Bedford, J. P. Stewart, M. J. Caslake, C. J. Packard, J. Shepherd, and D. M. Black. Stable isotope turnover studies of apolipoprotein B in combined hyperlipidaemia before and after treatment with Atorvastatin, a new HMG CoA reductase inhibitor. Circulation 94, Suppl. 1: 1-583, 1996.
16. Gaw, A., C. J. Packard, E. F. Murray, G. M. Lindsay, B. A. Griffin, M. J. Caslake, B. D. Vallance, A. R. Lorimer, and J. Shepherd. Effects of simvastatin on apoB metabolism and LDL subfraction distribution. Arterioscler. Thromb. 13:170-189, 1993.
17. Ginsberg, H. N., N.-A. Le, M. P. Short, R. Ramakrishnan, and R. J. Desnick. Suppression of apolipoprotein B production during treatment of cholesteryl ester storage disease with lovastatin: implications for regulation of apolipoprotein B synthesis. J. Clin. Invest. 80:1692-1697, 1987.
18. Grundy, S. M. HMG CoA reductase inhibitors for treatment of hypercholesterolaemia. N. Eng. J. Med. 319: 24-33, 1988.
19. Huff, M. W., D. E. Telford, and P. H. R. Barrett. Dietary fish oil plus lovastatin decreases both VLDL and LDL apoB production in miniature pigs. Arterioscler. Thromb. 12: 902-910, 1992.
20. Huff, M. W., D. E. Telford, P. H. R. Barrett, J. T. Bilheimer, and P. J. Gillies. Inhibition of hepatic ACAT decreases apoB secretion in miniature pigs fed a cholesterol-free diet. Arteriocler. Thromb. 14:1498-1508, 1994.
21. Kempen, H. J. M., M. Bermeer, E. de Wit, and L. M. Havekes. Vastatins inhibit cholesterol ester accumulation in human monocyte-derived macrophages. Artioscler. Thromb. 11: 146-153, 1991.
22. Kempen, H. J. M., J. F. C. Glatz, J. A. Gevers Leuven, H. A. van der Voort, and M. B. Katan. Serum lathosterol concentration is an indicator of whole-body cholesterol synthesis in humans. J. Lipid Res. 29:1149-1155, 1988.
23. Millar, J. S., A. H. Lichtenstein, M. Cuchel, G. G. Dolnikowski, D. L. Hachey, J. S. Cohn, and E. J. Schaefer. Impact of age on the metabolism of VLDL, IDL and LDL apolipoprotein B-100 in men. J. Lipid Res. 36:1155-1167, 1995.
24. Pajukunta, P. E., L. M. Valsta, A. Aro, P. Pietinen, T. Helio, and M. J. Tikkanen. The effects of the apolipoprotein B signal peptide (ins/del) and Xbal polymorphisms on plasma lipid response to dietary change. Atherosclerosis 122: 1-10, 1996.
25. Parhofer, K. F., P. H. R. Barrett, D. M. Brier, and G. Schonfeld. Determination of kinetic parameters of apolipoprotein B metabolism using ammo-acids labelled with stable isotopes. J. LlpidRes. 32:1311-1323, 1991.
26. Parker, T. S., D. J. McNamara, C. D. Brown, R. Kolb, E. H. Ahrens, A. W. Alberts, J. Tobert, J. Chen, and P. J. de Schepper. Plasma mevalonate as a measure of cholesterol synthesis in man. J. Clin. Invest. 74: 795-804, 1984.
27. Pfohl, M., R. P. Naoumova, C. Klass, K. J. Knisei, B. Jakofer, T. Risler, and G. R. Thompson. Acute and chronic effect on cholesterol biosynthesis of LDL-apheresis with or without concomitant HMGCoA reductase inhibitor therapy. J. LipidRes. 35: 1946-1955, 1994.
28. Sutherland, W. H. F., M. C. Robertson, S. A. Williamson, and E. R. Nye. Plasma noncholesterol sterols in male distance runners and sedentary men. Ear. J. Appl. Physiol. Occup. Physiol. 63: 119-123, 1991.
29. Tanaka, M., H. Jingami, H. Otani, M. Cho, Y. Ueda, H. Arai, Y. Nagano, T. Doi, M. Yokode, and T, Kita. Regulation of apolipoprotein B production and secretion in response to the change of intracellular cholesteryl ester content in rabbit hepatocytes. J.Biol. Chem. 268:12713-12718, 1993.
30. Thompson, G. R., R. P. Naoumova, and G. F. Watts. Role of cholesterol in regulating apolipoproteinB secretion by the liver. J. LipidRes. 37: 439-447, 1996.
31. Vega, G. L., C. East, and S. M. Grundy. Lovastatin therapy in familial dysbetalipoproteinaemia: effects on kinetics of apolipoprotein B. Atherosclerosis 70:131-143, 1988.
32. Vega, G. L., R. M. Krauss, and S. M. Grundy. Pravastatin therapy in primary moderate hypercholesterolaemia: changes in metabolism of apolipoprotein B-containing lipoproteins. J. Intern. Med. 227: 81-94, 1990.
33. Watts, G. F., M. H. Cummings, A. M. Umpleby, J. R. Quiney, R. Naoumova, G. R. Thompson, and P. H. Sönksen. Simvastatin decreases the hepatic secretion of very-low-density lipoprotein apolipoprotein B-100 in heterozygous familial hypercholesterolaemia: pathohysiological and therapeutic implications. Eur. J. Clin. Invest. 25: 559-567, 1995.
34. Watts, G. F., R. P. Nauomova, M. H. Cummings, A. M. Umpleby, B. M. Slavin, P. H. Sönksen, and G. R. Thompson. Direct correlation between cholesterol synthesis and hepatic secretion of apolipoprotein B-100 in normolipidaemic subjects. Metabolism 44:123-131, 1995.
35. Wetterau, J. R., and R. E. Gregg. Microsomal triglycéride transfer protein: insights into lipoprotein assembly and abetalipoproteinaemia. In: Atherosclerosis, edited by F. P. Woodford, J. Davignon, and A. Sniderman. Amsterdam: Elsevier Science, 1995, p. 40-44.
36. Wettesten, M., K. Boström, G. Bondjers, M. Jarfeldt, P. I. Norfeldt, M. Carella, O. Wiklund, J. Borén, and S. O. Olofsson. Pulse-chase studies of the synthesis of apolipoprotein B in a human hepatoma cell line, HepG2. Eur. J. Biochem. 149: 461-466, 1985.
37. Wu, X., N. Sakata, E. Lui, and H. N. Ginsberg. Evidence for a lack of regulation of the assembly and secretion of apolipoproteinB-containing lipoprotein from HepG2 cells by cholesteryl esters, J. Biol. Chem. 269: 12375-12382, 1994.
38. Yao, Z., and R. S. McLeod. Synthesis and secretion of hepatic apolipoprotein B-containing lipoproteins. Biochem. Biophys. Acta 1212:152-166, 1994.